Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death

World's Smallest and Thinnest High-Energy CRT-Ds and ICDs Offer new Features to Optimize Patient Management

NATICK, Massachusetts, May 6, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced the
launch and first implants of its ENERGEN(TM) and PUNCTUA(TM) cardiac
resynchronization therapy defibrillators (CRT-Ds) and implantable
cardioverter defibrillators (ICDs) in Europe and other international markets.
They are the world's smallest and thinnest high-energy devices to treat heart
failure and sudden cardiac death and offer excellent longevity.

"These devices build on the technological advancements of
COGNIS(R) and TELIGEN(R) by providing options to customize therapy for
individual patients," said Professor Joachim Winter, M.D., who performed one
of the first implants of the ENERGEN ICD with Dong-In Shin, M.D., at the
University Hospital Düsseldorf in Germany. "The small profile, coupled with
the 4-SITE(TM) connector system, allowed for an easy implant with a less
pronounced physical appearance for the patient."

"Physicians and patients will truly appreciate the longevity
of these devices since it may reduce the need for additional implant
surgeries," said Peter Lecher, M.D., who performed one of the first implants
of the ENERGEN CRT-D with Günther Prenner, M.D., at the Medical University in
Graz, Austria. "Additionally, the new therapy options, combined with the
LATITUDE(R) Patient Management system, increase the variety of diagnostic
parameters to help treat heart failure patients."

Most of the new ENERGEN and PUNCTUA devices offer the
4-SITE(TM) DF4 connector system option, designed to simplify the implant
procedure and comply with international connector standards. Additionally,
nearly all models are compatible with Boston Scientific's LATITUDE(R) Patient
Management system, which enables physicians to remotely monitor implantable
cardiac device patients between on-site office visits.

"The ENERGEN and PUNCTUA devices are designed to improve the
ability of physicians to deliver effective patient care," said Hank Kucheman,
Executive Vice President and Group President, Cardiology, Rhythm and Vascular
for Boston Scientific. "This new portfolio of products, built on our
tradition of innovation, continues our advantages in size, shape and
longevity and provides multiple therapy options to match specific patient
needs."

The Company received CE Mark approval for its ENERGEN and
PUNCTUA CRT-Ds and ICDs in October 2010. In the U.S., they are
investigational devices, limited by applicable law to investigational use and
not available for sale. The Company expects Food and Drug Administration
approval for the devices in late 2011 or early 2012.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project," "believe,"
"plan," "estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding new product launches and launch
cadence, regulatory approvals and compliance, clinical trials, product
features and performance, technology and competitive offerings. If our
underlying assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections expressed or implied by our forward-looking
statements. These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press release. As a
result, readers are cautioned not to place undue reliance on any of our
forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; product performance; regulatory
compliance; demographic trends; intellectual property; litigation; financial
market conditions; and future business decisions made by us and our
competitors. All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A - Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise any
forward-looking statements to reflect any change in our expectations or in
events, conditions or circumstances on which those expectations may be based,
or that may affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary statement is
applicable to all forward-looking statements contained in this document.

CONTACT: Geraldine Varoqui

+49-170-782-85-58

Head of Communication, EMEA

Boston Scientific

varoquig@bsci.com

.